We presented positive phase 3 ALCANZA clinical trial data for cutaneous T-cell #lymphoma w/ @TakedaOncology at #ASH16 http://glassdoor.com/slink.htm?key=vQA9o
We’re excited to be at #ASH16 to discuss new research in #Hodgkin #lymphoma, as part of 18 abstracts & 8 oral presentations. http://glassdoor.com/slink.htm?key=vQA9Z
We’re wearing red for #BCAM. Let’s make the future brighter for everyone touched by lymphoma #LightItRed http://glassdoor.com/slink.htm?key=vI3M7
Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia
-SGN-CD123A, A Novel ADC, Represents Seattle Genetics’ Second Clinical ADC Program Focused on AML-
http://glassdoor.com/slink.htm?key=vI3MY
We’re supporting Fred Hutch in the fight against cancer with our biggest Obliteride team ever! Check out our team page and join us in the fight. http://glassdoor.com/slink.htm?key=vIhaO
We’re proud to be #1 in Monster’s blog on 10 companies with awesome training & development programs http://glassdoor.com/slink.htm?key=vIqen
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
http://glassdoor.com/slink.htm?key=vIxq5
CEO & George Washington University alum, Clay Siegall profiled in GWU's "Medicine + Health" - In a profile by his alma mater, Clay describes how he came to discover biomedical science and eventually start Seattle Genetics. http://glassdoor.com/slink.htm?key=vIxNn
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 http://glassdoor.com/slink.htm?key=vIGVJ
Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015 http://glassdoor.com/slink.htm?key=vIGVS